Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board
Scinai Immunotherapeutics (Nasdaq: SCNI) has appointed Dr. Jonathan Sadeh to its Scientific Advisory Board. Dr. Sadeh, former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, brings over 20 years of experience in drug development and clinical research. He will focus on advancing Scinai's lead IL-17 program and VHH antibody pipeline. At BMS, he led multiple drug approvals, including Sotyktu for psoriasis. Dr. Sadeh previously held senior positions at Sanofi, AstraZeneca, and Schering-Plough, and earned his MD from Mount Sinai School of Medicine and M.Sc. from Harvard Medical School.
Scinai Immunotherapeutics (Nasdaq: SCNI) ha nominato il Dr. Jonathan Sadeh nel suo Comitato Scientifico. Il Dr. Sadeh, ex Vicepresidente Senior di Ricerca e Sviluppo Immunologico presso Bristol-Myers Squibb, porta con sé oltre 20 anni di esperienza nello sviluppo di farmaci e nella ricerca clinica. Si concentrerà sull'avanzamento del programma IL-17 di Scinai e della pipeline degli anticorpi VHH. Presso BMS, ha guidato molteplici approvazioni di farmaci, incluso Sotyktu per la psoriasi. Il Dr. Sadeh ha ricoperto precedentemente posizioni di alto livello presso Sanofi, AstraZeneca e Schering-Plough, e ha conseguito il suo MD presso la Mount Sinai School of Medicine e il M.Sc. presso la Harvard Medical School.
Scinai Immunotherapeutics (Nasdaq: SCNI) ha nombrado al Dr. Jonathan Sadeh en su Consejo Asesor Científico. El Dr. Sadeh, ex Vicepresidente Senior de I+D en Inmunología de Bristol-Myers Squibb, aporta más de 20 años de experiencia en el desarrollo de medicamentos y en la investigación clínica. Se centrará en avanzar el programa IL-17 de Scinai y la cartera de anticuerpos VHH. En BMS, lideró múltiples aprobaciones de medicamentos, incluido Sotyktu para la psoriasis. El Dr. Sadeh ocupó anteriormente altos cargos en Sanofi, AstraZeneca y Schering-Plough, y obtuvo su MD en la Mount Sinai School of Medicine y un M.Sc. en la Harvard Medical School.
Scinai Immunotherapeutics (Nasdaq: SCNI)는 Jonathan Sadeh 박사를 과학 자문 위원회에 임명했습니다. Sadeh 박사는 Bristol-Myers Squibb의 면역학 R&D 수석 부사장을 역임했으며, 20년 이상의 약물 개발 및 임상 연구 경험을 보유하고 있습니다. 그는 Scinai의 IL-17 프로그램과 VHH 항체 파이프라인을 발전시키는 데 집중할 것입니다. BMS에서는 Sotyktu를 포함한 여러 약물 승인 과정을 이끌었습니다. Sadeh 박사는 이전에 Sanofi, AstraZeneca 및 Schering-Plough에서 고위직을 맡았으며, Mount Sinai School of Medicine에서 MD를, Harvard Medical School에서 M.Sc.를 취득했습니다.
Scinai Immunotherapeutics (Nasdaq: SCNI) a nommé Dr. Jonathan Sadeh au sein de son Conseil Consultatif Scientifique. Le Dr. Sadeh, ancien Vice-Président Senior de la R&D en immunologie chez Bristol-Myers Squibb, apporte plus de 20 ans d'expérience dans le développement de médicaments et la recherche clinique. Il se concentrera sur l'avancement du programme IL-17 de Scinai et de son pipeline d'anticorps VHH. Chez BMS, il a dirigé plusieurs approbations de médicaments, y compris Sotyktu pour le psoriasis. Le Dr. Sadeh a précédemment occupé des postes de haut niveau chez Sanofi, AstraZeneca et Schering-Plough, et a obtenu son MD de la Mount Sinai School of Medicine et un M.Sc. de la Harvard Medical School.
Scinai Immunotherapeutics (Nasdaq: SCNI) hat Dr. Jonathan Sadeh in sein Wissenschaftlicher Beirat berufen. Dr. Sadeh, ehemaliger Senior Vice President für Immunologie F&E bei Bristol-Myers Squibb, bringt über 20 Jahre Erfahrung in der Arzneimittelentwicklung und klinischen Forschung mit. Er wird sich auf die Weiterentwicklung von Scinais führendem IL-17-Programm und der VHH-Antikörper-Pipeline konzentrieren. Bei BMS leitete er mehrere Arzneimittelzulassungen, darunter Sotyktu für Psoriasis. Dr. Sadeh hatte zuvor leitende Positionen bei Sanofi, AstraZeneca und Schering-Plough inne und erhielt seinen MD von der Mount Sinai School of Medicine sowie seinen M.Sc. von der Harvard Medical School.
- Addition of highly experienced executive with over 20 years in drug development
- Track record of successful drug approvals across multiple therapeutic areas
- Strategic expertise in advancing immunology programs and clinical development
- None.
Dr. Sadeh is an accomplished physician-scientist with over 20 years of experience in drug development and clinical research. He spent the last five years at Bristol-Myers Squibb (BMS), where he held multiple senior leadership positions, including Senior Vice President and Global Programs Head for Immunology, Cardiovascular, and Neuroscience; Immunology Therapeutic Area Head; and China R&D Head. Throughout his career, he has been responsible for multiple drug approvals across various fields, including pulmonary, rheumatology, dermatology, gastroenterology, and neurology. His most recent achievement is the approval of Sotyktu, a first-in-class TYK2 inhibitor for the treatment of psoriasis. Prior to BMS, Dr. Sadeh held senior leadership positions at Sanofi, AstraZeneca, and Schering-Plough.
Dr. Sadeh earned his MD in Medicine from the Mount Sinai School of Medicine and an M.Sc. degree in Clinical Research from Harvard Medical School. He completed his fellowship in pulmonary and critical care at Harvard Medical School. He began his medical career as an academic researcher at Brigham and Women's Hospital.
Dr. Jonathan Sadeh commented: "As a physician, scientist, and drug developer, I am deeply committed to advancing innovative therapies for patients with significant unmet medical needs. Scinai's use of VHH antibodies as a bio-better approach leverages the unique attributes of VHH antibodies to overcome the shortcomings of other approved biologics. This presents a unique way to provide patients with treatments that truly address their conditions in a meaningful way. The opportunity to collaborate with esteemed institutions like Max Planck and UMG further strengthens my belief in Scinai's potential. I look forward to contributing to Scinai's mission and helping establish it as a globally recognized leader in scientifically driven drug development".
Amir Reichman, CEO of Scinai, commented: "We are thrilled to welcome Dr. Jonathan Sadeh to our Scientific Advisory Board. His extensive experience and proven track record in drug development and clinical research will be invaluable as we continue to advance our pipeline of innovative I&I biological products. We look forward to his contributions and insights as we strive to bring transformative therapies to patients in need."
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (nanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services for early stage biotech drug development projects.
Company website: www.scinai.com.
Company Contacts
Investor Relations | +972 8 930 2529 | ir@scinai.com
Business Development | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. Examples of such statements include, but are not limited to, the development of meaningful drugs and the potential of Scinai's NanoAb program. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to; the risk that the Company will otherwise be unable to remain compliant with the continued listing requirements of Nasdaq; a delay in the commencement and results of pre-clinical and clinical studies, including the Phase 1/2a study for psoriasis; the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; inability to develop meaningful drugs; lower than anticipated revenues of Scinai's CDMO business in 2024 and thereafter; failure to sign agreements with other potential clients of the CDMO business; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in
Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/dr-jonathan-sadeh-former-senior-vice-president-of-immunology-rd-at-bristol-myers-squibb-joins-scinai-immunotherapeutics-scientific-advisory-board-302317465.html
SOURCE Scinai Immunotherapeutics Ltd.
FAQ
Who is the newest member of Scinai Immunotherapeutics' (SCNI) Scientific Advisory Board?
What will be Dr. Sadeh's role at Scinai Immunotherapeutics (SCNI)?
What was Dr. Sadeh's most recent achievement at Bristol-Myers Squibb before joining SCNI?
